# Minocycline in MS: Confirmation of Benefit

> **NCT04291456** · PHASE3 · TERMINATED · sponsor: **University of Calgary** · enrollment: 9 (actual)

## Conditions studied

- Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** Minocycline 100mg

## Key facts

- **NCT ID:** NCT04291456
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-31
- **Primary completion:** 2022-12-16
- **Final completion:** 2022-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Completion is not possible due to recruitment concerns
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291456, "Minocycline in MS: Confirmation of Benefit". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04291456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*